Technology Guidance

Dabrafenib in combination with trametinib

for low-grade glioma and relapsed or refractory high-grade glioma, with BRAF V600E mutations

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Dabrafenib in combination with trametinib for the following indications:
  - treatment of paediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy; and
  - treatment of paediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.

in view of acceptable clinical effectiveness and safety, and an acceptable pricing proposal by the company.

Funding status

Dabrafenib 50 mg, 75 mg capsules, and 10 mg dispersible tablet, and trametinib 0.5 mg, 2 mg tablets, and 4.7 g powder for oral solution, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 April 2026.

Clinical indications, subsidy class and MediShield Life claim limits for dabrafenib and trametinib are provided in the Annex.

Published: 6 February 2026

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Approved clinical indication	Subsidy class (implementation date)	MediShield Life claim limit per month (implementation date)
Dabrafenib 50 mg, 75 mg capsules Dabrafenib 10 mg dispersible tablet Trametinib 0.5 mg, 2 mg tablets Trametinib 4.7 g powder for oral solution	Dabrafenib in combination with trametinib for the treatment of paediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. Treatment must be discontinued following disease progression based on the Response Assessment in Neuro-Oncology (RANO) criteria.	MAF (1 April 2026)	$3800 (1 April 2026)
	Dabrafenib in combination with trametinib for the treatment of paediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. Treatment must be discontinued following disease progression based on the Response Assessment in Neuro-Oncology (RANO) criteria.	MAF (1 April 2026)	$3800 (1 April 2026)

Abbreviations: BRAF, B-rapidly accelerated fibrosarcoma; MAF, Medication Assistance Fund.

Agency for Care Effectiveness - ACE Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

Agency for Care Effectiveness, Ministry of Health, Singapore
Email: ACE_HTA@moh.gov.sg